Ultimate magazine theme for WordPress.

BTC
$9,300.35
+1.57%
ETH
$269.22
+0.53%
LTC
$136.49
+0.72%
DASH
$160.82
+1.34%
XMR
$101.66
+2.72%
NXT
$0.04
0%
ETC
$8.53
-1.02%
DOGE
$0.00
+1.82%
ZEC
$109.00
-4.52%
BTS
$0.06
0%
DGB
$0.01
+8.68%
XRP
$0.43
+0.77%
BTCD
$23.36
PPC
$0.41
-21.81%
CRAIG
$0.00
XBS
$0.02
0%
XPY
$0.05
0%
PRC
$0.01
0%
YBC
$26.04
0%
DANK
$0.00

Bristol-Myers Squibb Co. to Collaborate With FameWave for Non-Small Cell Lung Cancer Study

398

FameWave Ltd., a privately held group developing CM-24, which is being acquired by Kitov Pharma Ltd. (KTOV), disclosed early Friday a clinical collaboration with Bristol Myers Squibb Company (BMY), pushing shares of Kitov by more than 18% in the pre-market.

- Advertisement -

Shares of Bristol Myers were up 0.7% in the pre-market.

The collaboration is to evaluate the combination of CM-24, FameWave’s monoclonal antibody targeting the novel immune checkpoint carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), with nivolumab (Opdivo), a PD-1 inhibitor, in patients with non-small cell lung cancer (NSCLC).

FameWave and Bristol Myers Squibb will coordinate on the protocol design for the phase 1/2 clinical trial. Under the terms of the deal, FameWave will fund and sponsor the study and Bristol Myers Squibb will supply nivolumab.

Just-released report names Cannabis Stock of the Year for 2019! Their last pick has seen a +1,200% return since he released it!

This stock has all of the makings of the next great cannabis stock – early-mover advantage, international exposure and influential partnerships, plus it has a product that is unlike anything else on the market…

You will also receive a free, weekly newsletter to stay on top of the latest industry trends, read analysis on promising cannabis stocks, and more. Click here to receive your Free Report immediately!

The “collaboration is a crucial step to begin evaluation of CM-24 in combination with a PD-1 inhibitor,” said Michael Schickler, CEO of FameWave. “We look forward to evaluating CM-24 in NSCLC since we believe it has a great potential as a novel immune checkpoint to be used in combination therapies for a variety of hard-to-treat cancers.”

Comments